Gabapentin Solution
Product Images NDC 31722-069

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 31722-069). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Camber Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Bottel-carton (Bottel Carton)

Packaging label for Gabapentin Oral Solution 250 mg per 5 mL by Camber Pharmaceuticals, Inc. The label indicates a 470 mL bottle with NDC 31722-069-47. It includes storage instructions to refrigerate at 2°C to 8°C (36°F to 46°F), pharmacy dispensing notes, and manufacturer details, including Annora Pharma Pvt. Ltd. in Telangana, India.*

FDA Label Image

Bottel-label (Bottel Label)

Label for Gabapentin Oral Solution 250 mg per 5 mL, a 470 mL oral solution by Camber Pharmaceuticals, Inc. The label includes storage instructions to refrigerate at 2°C to 8°C, a pharmacist dispensing notice, a barcode, and U.S. contact information. Manufactured for Camber Pharmaceuticals, Piscataway, NJ.*

FDA Label Image

Camberlogo---2 (Camberlogo 2)

FDA Label Image

Camberlogo (Camberlogo)

FDA Label Image

Gabapentios-fig1 (Gabapentios Fig1)

Line graph depicting mean pain score over 8 weeks comparing placebo to gabapentin 3600 mg/day. The x-axis shows weeks from baseline through week 8, and the y-axis shows mean pain scores from 0 to 10. The graph includes a 4-week dose titration period followed by a 4-week fixed dose period. Gabapentin shows a decreasing pain score trend, while placebo remains relatively constant.*

FDA Label Image

Gabapentios-fig2 (Gabapentios Fig2)

A line graph showing mean pain score over seven weeks during a study period including a 3-week dose titration and 4-week fixed dose. It compares placebo, gabapentin 1800 mg/day, and gabapentin 2400 mg/day, indicating changes in pain scores over time for each group.*

FDA Label Image

Gabapentios-fig3 (Gabapentios Fig3)

A bar chart titled 'Proportion of Responders (Patients with ≥ 50% reduction in pain score) at Endpoint: Controlled PHN Studies' comparing placebo (PBO) and gabapentin (GBP) doses. Study 1 shows 12% responders for placebo and 29% for GBP 3600 mg. Study 2 shows 14% for placebo, 32% for GBP 1800 mg, and 34% for GBP 2400 mg. Significance levels are noted with ** p < 0.01 and *** p < 0.001.*

FDA Label Image

Gabapentios-fig4 (Gabapentios Fig4)

A scatter plot graph depicting the percentage difference versus daily dose (mg) for gabapentin across three studies labeled a, b, and c. The x-axis represents daily dose ranging from 600 to 1800 mg, and the y-axis represents difference percentage from 2% to 22%. Data points from study a, b, and c are shown with distinct markers, illustrating variability in percentage difference at various doses.*

FDA Label Image

Gabapentios-structure (Gabapentios Structure)

Chemical structure of gabapentin showing a cyclohexane ring with an amino group (H2N) and a carboxyl group (COOH) attached to a central carbon.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.